Glenmark Pharma gets USFDA nod for drug for patients on dialysis

Glenmark Pharma gets USFDA nod for drug for patients on dialysis "Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (USFDA) for Sevelamer Hydrochloride tablets in the strengths of 400 mg and 800 mg," the company said in a BSE filing.

No comments:

Post a Comment